Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PEXEVA vs CELEXA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Paroxetine is a selective serotonin reuptake inhibitor (SSRI); it potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking reuptake of serotonin into presynaptic neurons.
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Social anxiety disorder,Generalized anxiety disorder,Posttraumatic stress disorder,Premenstrual dysphoric disorder,Vasomotor symptoms associated with menopause
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Social anxiety disorder,Generalized anxiety disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
Initial 10 mg orally once daily, increased gradually based on response and tolerability; maximum 50 mg once daily (paroxetine hydrochloride equivalent).
20 mg orally once daily initially, may increase to 40 mg once daily after at least 1 week; maximum 40 mg/day.
60-120 hours (chronic dosing); steady-state achieved in 4-5 weeks
Terminal elimination half-life is approximately 35 hours (range 23–45 h) in healthy adults. This long half-life allows once-daily dosing; steady state is reached in about 1 week. In elderly patients, half-life may extend to 45–90 hours.
Extensively metabolized by CYP2D6; minor pathways include CYP3A4; undergoes oxidative and conjugation reactions.
Hepatic via CYP2C19 (major), CYP3A4, and CYP2D6; active metabolites: S-demethylcitalopram and didemethylcitalopram.
Primarily renal (70% as metabolites, 2% unchanged); fecal (27%)
Primarily renal: 75% as metabolites (10% as parent citalopram, 65% as desmethylcitalopram, didesmethylcitalopram, and citalopram-N-oxide). Fecal excretion accounts for approximately 20% of the dose. Biliary excretion minimal.
98% bound to albumin and α1-acid glycoprotein
Approximately 80% bound to plasma proteins (primarily albumin and α1-acid glycoprotein). Binding is independent of drug concentration.
20-30 L/kg; large Vd indicates extensive tissue distribution
Mean Vd is 12 L/kg (range 8–16 L/kg). This large Vd indicates extensive extravascular distribution, including CNS penetration. High Vd contributes to the long half-life.
Oral: 50-80% (first-pass metabolism)
Oral bioavailability is approximately 80% (range 60–90%). No significant first-pass metabolism. Food does not affect bioavailability.
Creatinine clearance (Cr Cl) 30-59 m L/min: initially 10 mg once daily, maximum 40 mg once daily. Cr Cl < 30 m L/min or hemodialysis: initially 10 mg once daily, maximum 30 mg once daily.
GFR >20 m L/min: no adjustment; GFR ≤20 m L/min: maximum 20 mg/day; not recommended for GFR <10 m L/min.
Child-Pugh Class B or C: initially 10 mg once daily, maximum 30 mg once daily. Child-Pugh Class A: no adjustment recommended.
Child-Pugh Class A: 10 mg once daily; Child-Pugh Class B or C: maximum 20 mg/day with careful titration.
Not FDA-approved for patients < 18 years; use not recommended due to increased risk of suicidal thoughts and behaviors.
Adolescents 12-17 years: 10 mg orally once daily initially, may increase to 20 mg once daily after 3 weeks; maximum 20 mg/day. Children <12 years: not approved.
Initial dose 10 mg orally once daily; maximum 40 mg once daily. Elderly patients may have increased plasma concentrations and require slower titration.
Patients >60 years: 10 mg orally once daily initially, maximum 20 mg once daily.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Suicidality in children, adolescents, and young adults,Serotonin syndrome,Discontinuation syndrome (withdrawal),Activation of mania/hypomania,Seizures,Angle-closure glaucoma,Increased intraocular pressure,Hyponatremia,Abnormal bleeding,Sexual dysfunction,Bone fracture risk,Drug interactions with MAOIs and other serotonergic drugs
QT prolongation, serotonin syndrome, hyponatremia, increased risk of bleeding, activation of mania/hypomania, seizures, angle-closure glaucoma, sexual dysfunction, and discontinuation syndrome.
Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI,Concurrent use with tryptophan,Concurrent use with pimozide,Known hypersensitivity to paroxetine or any excipient
Concomitant use with MAOIs or within 14 days of MAOI use, concomitant use with pimozide, hypersensitivity to citalopram or any excipients.
Avoid grapefruit and grapefruit juice, as they can increase paroxetine levels and risk of toxicity. Alcohol may exacerbate CNS depression and should be limited. No other significant food interactions.
No specific food interactions. Avoid grapefruit and grapefruit juice as they may increase citalopram levels via CYP3A4 inhibition. Alcohol may exacerbate CNS depression and should be avoided.
PEXEVA (paroxetine) is classified as FDA Pregnancy Category D. First trimester exposure is associated with a 1.5- to 2-fold increased risk of congenital cardiac malformations, particularly ventricular septal defects, and an increased risk of omphalocele and craniosynostosis. Third trimester exposure may result in neonatal adaptation syndrome (e.g., respiratory distress, jitteriness, poor feeding, persistent crying) and rare cases of persistent pulmonary hypertension of the newborn (PPHN). The risk is dose-dependent and highest with doses above 25 mg/day.
First trimester: Data insufficient to definitively assess major malformation risk; some studies suggest small increased risk of cardiac defects (e.g., septal defects). Second/Third trimester: Risk of persistent pulmonary hypertension of the newborn (PPHN), preterm birth, low birth weight; late third trimester exposure may cause neonatal adaptation syndrome (irritability, respiratory distress, feeding difficulties).
Paroxetine is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.5-0.7. Though relative infant doses are low (typically <2% of maternal weight-adjusted dose), adverse effects such as irritability, poor feeding, and drowsiness have been reported. Caution is advised, particularly with high maternal doses; non-pharmacologic strategies or alternative antidepressants with more favorable lactation profiles may be preferred.
Citalopram is excreted into breast milk; average infant dose relative to maternal weight-adjusted dose is 3.9% (range 1.7-8.5%). Milk-to-plasma ratio (M/P) approximately 1.5. Cases of adverse effects in breastfed infants (excessive somnolence, poor feeding) reported; caution with higher maternal doses. Benefits of breastfeeding generally outweigh risks for mild cases, but alternative agents with lower M/P (e.g., sertraline, paroxetine) may be preferred for moderate-severe depression.
Pregnancy can alter paroxetine pharmacokinetics, leading to increased clearance and reduced plasma concentrations, particularly in the second and third trimesters. Dose adjustments (e.g., up to 1.5-2 times the pre-pregnancy dose) may be required to maintain therapeutic efficacy. However, higher doses increase fetal risk, so lowest effective dose should be used. Tapering or switching to a safer agent (e.g., fluoxetine or sertraline) is often considered. Postpartum, doses should be gradually reduced to pre-pregnancy levels to avoid toxicity.
Pregnancy may reduce citalopram plasma concentrations by 30-50% due to increased volume of distribution and enhanced hepatic clearance (CYP2C19 induction). Dose adjustment should be guided by clinical response (depressive symptom monitoring) and trough serum concentrations if available. A 30-50% dose increase (e.g., from 20 mg to 30-40 mg) may be needed, especially in third trimester. Postpartum: Dose should be tapered back to pre-pregnancy levels within 1–2 weeks to avoid toxicity.
Pexeva (paroxetine mesylate) is an SSRI antidepressant. Due to its short half-life, abrupt discontinuation may cause withdrawal syndrome. It is also indicated for panic disorder, OCD, and social anxiety disorder. Use with caution in patients with narrow-angle glaucoma, as it can precipitate acute angle closure. Monitor for hyponatremia in elderly patients. Avoid concurrent use with MAOIs or other serotonergic agents due to risk of serotonin syndrome.
Celexa (citalopram) is an SSRI antidepressant. Key pearls: (1) Max dose 40 mg/day due to QT prolongation risk at higher doses; (2) CYP2C19 and CYP3A4 metabolism; avoid with MAOIs and linezolid; (3) Onset of therapeutic effect takes 2-4 weeks; (4) More selective for serotonin reuptake than fluoxetine or paroxetine, with fewer drug interactions; (5) May cause mild SIADH in elderly; (6) Abrupt discontinuation can cause withdrawal syndrome; (7) Electrolyte monitoring recommended in patients at risk for QT prolongation.
Take exactly as prescribed; do not stop suddenly. If you miss a dose, take it as soon as you remember unless it is close to the next dose. Do not double doses.,May take up to 4 weeks to feel full benefit. Continue medication even if you feel better.,Avoid alcohol and grapefruit juice. Grapefruit can increase Pexeva levels and side effects.,May cause drowsiness, dizziness, or blurred vision. Do not drive or operate machinery until you know how Pexeva affects you.,Report any suicidal thoughts, agitation, or worsening depression immediately to your doctor.,Common side effects include nausea, dry mouth, constipation, decreased appetite, and sexual dysfunction. These often improve over time.
Take exactly as prescribed; do not increase dose without consulting your doctor.,It may take 2-4 weeks to feel the full benefit; do not stop abruptly.,Avoid alcohol while taking this medication.,Report any symptoms of serotonin syndrome (agitation, hallucinations, rapid heart rate, fever, muscle stiffness) immediately.,Notify your doctor if you experience unusual bleeding or bruising, or if you have a history of QT prolongation or electrolyte disturbances.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PEXEVA vs CELEXA, answered by our medical review team.
PEXEVA is a SSRI Antidepressant that works by Paroxetine is a selective serotonin reuptake inhibitor (SSRI); it potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.. CELEXA is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking reuptake of serotonin into presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PEXEVA and CELEXA depend on the specific clinical indication. These are both SSRI Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PEXEVA is: Initial 10 mg orally once daily, increased gradually based on response and tolerability; maximum 50 mg once daily (paroxetine hydrochloride equivalent).. The standard adult dose of CELEXA is: 20 mg orally once daily initially, may increase to 40 mg once daily after at least 1 week; maximum 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PEXEVA and CELEXA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PEXEVA is classified as Category C. PEXEVA (paroxetine) is classified as FDA Pregnancy Category D. First trimester exposure is associated with a 1.5- to 2-fold increased risk of congenital cardiac malformations, part. CELEXA is classified as Category C. First trimester: Data insufficient to definitively assess major malformation risk; some studies suggest small increased risk of cardiac defects (e.g., septal defects). Second/Third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.